A carregar...
Spheramine for treatment of Parkinson’s disease
Spheramine (Bayer Schering Pharma AG, Berlin, Germany) is currently being tested as a new approach for the treatment of Parkinson’s disease (PD). It consists of an active component of cultured human retinal pigment epithelial (hRPE) cells, attached to an excipient part of crosslinked porcine gelatin...
Na minha lista:
| Publicado no: | Neurotherapeutics |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer-Verlag
2008
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5084167/ https://ncbi.nlm.nih.gov/pubmed/18394567 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.nurt.2008.02.006 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|